美国银行将Vertex制药公司升级为“买家”,尽管最近收入出现亏损,但价格目标是567美元。 Bank of America upgraded Vertex Pharmaceuticals to a "buy" with a price target of $567, despite recent earnings miss.

美国银行将Vertex制药公司的价格目标提高至567美元, Bank of America raised Vertex Pharmaceuticals' price target to $567, a 15.08% potential upside, with a "buy" rating. 开发细胞纤维化治疗的生物技术公司发现,尽管最近收入出现亏损,但Orion组合解决方案公司和B.Metzler公司等机构投资者的股票持有量却有所上升。 The biotech firm, which develops cystic fibrosis treatments, saw its stock holdings rise from institutional investors like Orion Portfolio Solutions and B. Metzler, despite a recent earnings miss. Vertex公司的市场上限为1 265.2亿美元,P/E比率为223.95。 Vertex's market cap stands at $126.52 billion, with a P/E ratio of -223.95.